Aspergillosis due to Voriconazole Highly Resistant Aspergillus fumigatus and Recovery of Genetically Related Resistant Isolates From Domiciles
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Azole resistance is an emerging problem in Aspergillus fumigatus and complicates the management of patients with Aspergillus-related diseases. Selection of azole resistance may occur through exposure to azole fungicides in the environment. In the Netherlands a surveillance network was used to investigate the epidemiology of resistance selection in A. fumigatus. METHODS: Clinical A. fumigatus isolates were screened for azole resistance in 8 university hospitals using azole agar dilution plates. Patient information was collected using an online questionnaire and azole-resistant A. fumigatus isolates were analyzed using gene sequencing, susceptibility testing, and genotyping. Air sampling was performed to investigate the presence of resistant isolates in hospitals and domiciles. RESULTS: Between December 2009 and January 2011, 1315 A. fumigatus isolates from 921 patients were screened. A new cyp51A-mediated resistance mechanism (TR46/Y121F/T289A) was observed in 21 azole-resistant isolates from 15 patients in 6 hospitals. TR46/Y121F/T289A isolates were highly resistant to voriconazole (minimum inhibitory concentration ≥16 mg/L). Eight patients presented with invasive aspergillosis due to TR46/Y121F/T289A, and treatment failed in all 5 patients receiving primary therapy with voriconazole. TR46/Y121F/T289A Aspergillus fumigatus was recovered from 6 of 10 sampled environmental sites. CONCLUSIONS: We describe the emergence and geographical migration of a voriconazole highly resistant A. fumigatus that was associated with voriconazole treatment failure in patients with invasive aspergillosis. Recovery of TR46/Y121F/T289A from the environment suggests an environmental route of resistance selection. Exposure of A. fumigatus to azole fungicides may facilitate the emergence of new resistance mechanisms over time, thereby compromising the use of azoles in the management of Aspergillus-related diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The highest rates of both azole and echinocandin resistance are observed in Candida glabrata and Candida tropicalis30 (Table 1).”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [30]
Citations
Cites
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/588660 · Cited by 4,917
Walsh, T. J., Anaissie, E. J., Denning, D. W., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Segal, B. H., Steinbach, W. J., Stevens, D. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/525258 · Cited by 2,706
Howard, S. J., Cerar, D., Anderson, M. J., Albarrag, A., Fisher, M. C., Pasqualotto, A. C., Laverdiere, M., Arendrup, M. C., Perlin, D. S., & Denning, D. W. (2009) · Emerging Infectious Diseases · doi:10.3201/eid1507.090043 · Cited by 750
Emergence of Azole Resistance in Aspergillus fumigatus and Spread of a Single Resistance Mechanism
Snelders, E., van der Lee, H. A. L., Kuijpers, J., Rijs, A. J. M. M., Varga, J., Samson, R. A., Mellado, E., Donders, A. R. T., Melchers, W. J. G., & Verweij, P. E. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050219 · Cited by 727
Self-citationAzole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?
Verweij, P. E., Snelders, E., Kema, G. H., Mellado, E., & Melchers, W. J. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70265-8 · Cited by 604
Self-citationMellado, E., Garcia-Effron, G., Alcázar-Fuoli, L., Melchers, W. J. G., Verweij, P. E., Cuenca-Estrella, M., & Rodríguez-Tudela, J. L. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01092-06 · Cited by 490
Self-citationClinical Implications of Azole Resistance in Aspergillus fumigatus, the Netherlands, 2007–2009
van der Linden, J. W. M., Snelders, E., Kampinga, G. A., Rijnders, B. J. A., Mattsson, E., Debets-Ossenkopp, Y. J., Kuijper, E. J., Van Tiel, F. H., Melchers, W. J. G., & Verweij, P. E. (2011) · Emerging Infectious Diseases · doi:10.3201/eid1710.110226 · Cited by 446
Self-citationTriazole Fungicides Can Induce Cross-Resistance to Medical Triazoles in Aspergillus fumigatus
Snelders, E., Camps, S. M. T., Karawajczyk, A., Schaftenaar, G., Kema, G. H. J., van der Lee, H. A., Klaassen, C. H., Melchers, W. J. G., & Verweij, P. E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031801 · Cited by 427
Self-citationPossible Environmental Origin of Resistance of Aspergillus fumigatus to Medical Triazoles
Snelders, E., Huis in 't Veld, R. A. G., Rijs, A. J. M. M., Kema, G. H. J., Melchers, W. J. G., & Verweij, P. E. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.00231-09 · Cited by 423
Self-citationMultiple-Triazole–Resistant Aspergillosis
Verweij, P. E., Mellado, E., & Melchers, W. J. G. (2007) · New England Journal of Medicine · doi:10.1056/nejmc061720 · Cited by 380
Self-citation
Research works printed but not linked: 1
- Van der Linden, 2009, Azole containing agar plates as a screening tool for azole resistance of Aspergillus fumigatus, Mycoses, 52, S1
Cited by
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
“about sources of aspergillosis, including the spread of azole-resistant strains [17, 25], although there is debate whether such surveillance is of value for routine patient care [26, 27].”
BackgroundUllmann, A. J., Aguado, J. M., Arikan-Akdagli, S., Denning, D. W., Groll, A. H., Lagrou, K., Lass-Flörl, C., Lewis, R. E., Munoz, P., Verweij, P. E., et al. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.01.002 · Cited by 1,556
“As resistant spores are present in ambient air, patients may present with azole-resistant Aspergillus disease without previous azole therapy [113,114].”
BackgroundMethodSelf-citationMechanisms of Antifungal Drug Resistance
Cowen, L. E., Sanglard, D., Howard, S. J., Rogers, P. D., & Perlin, D. S. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019752 · Cited by 647
Drug resistance and tolerance in fungi.
Berman, J., & Krysan, D. J. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0322-2 · Cited by 642
Verweij, P. E., Chowdhary, A., Melchers, W. J. G., & Meis, J. F. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ885 · Cited by 561
“Azole resistant 100% [44] Culture-positive patients with proven and probable IPA treated with voriconazole (5/5) 86% [24, 44, 60] 7 cases of azole-resistant CNS IA have been reported, of which 6 were fatal.”
BackgroundInfluentialSelf-citationAntifungal resistance: current trends and future strategies to combat
Wiederhold, N. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s124918 · Cited by 468
“These include the TR 34 / L98H, which causes pan-azole resistance, and TR 46 /Y121F/ T289A, which causes reduced posaconazole potency and high-level resistance to voriconazole and posaconazole.(43,44) Both of these mutations have been documented in isolates collected from patients with invasive aspergillosis without a…”
BackgroundEmerging Threats in Antifungal-Resistant Fungal Pathogens
Sanglard, D. (2016) · Frontiers in Medicine · doi:10.3389/fmed.2016.00011 · Cited by 416
“fumigatus isolate had never received azole treatment before (86).”
BackgroundChowdhary, A., Kathuria, S., Xu, J., & Meis, J. F. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003633 · Cited by 380
“hospitals in the Netherlands [24].”
BackgroundProspective Multicenter International Surveillance of Azole Resistance in Aspergillus fumigatus
van der Linden, J. W. M., Arendrup, M. C., Warris, A., Lagrou, K., Pelloux, H., Hauser, P. M., Chryssanthou, E., Mellado, E., Kidd, S. E., Tortorano, A. M., et al. (2015) · Emerging Infectious Diseases · doi:10.3201/eid2106.140717 · Cited by 371
Self-citationVerweij, P. E., Ananda-Rajah, M., Andes, D., Arendrup, M. C., Brüggemann, R. J., Chowdhary, A., Cornely, O. A., Denning, D. W., Groll, A. H., Izumikawa, K., et al. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.08.001 · Cited by 330
“…and in hospitals located in several European countries as well as India, the Middle-East and Africa (Snelders et al., 2009; van der Linden et al., 2011; van der Linden et al., 2013; Badali et al., 2013; Ahmad et al., 2014; Chowdhary et al., 2014a; Chowdhary et al., 2014b; Bader et al., 2015).”
BackgroundResultInfluentialSelf-citationLestrade, P. P., Bentvelsen, R. G., Schauwvlieghe, A. F. A. D., Schalekamp, S., van der Velden, W. J. F. M., Kuiper, E. J., van Paassen, J., van der Hoven, B., van der Lee, H. A., Melchers, W. J. G., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy859 · Cited by 310
“Voriconazole resistance was dominated by mutations associated with environmental resistance selection, accounting for 87% of resistance mutations [7, 11, 12].”
BackgroundResultSelf-citationClinical implications of globally emerging azole resistance in Aspergillus fumigatus
Meis, J. F., Chowdhary, A., Rhodes, J. L., Fisher, M. C., & Verweij, P. E. (2016) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2015.0460 · Cited by 308
Self-citationThe rapid emergence of antifungal-resistant human-pathogenic fungi
Lockhart, S. R., Chowdhary, A., & Gold, J. A. W. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00960-9 · Cited by 308
“…two most widely dispersed CYP51A mutations are TR 34 /L98H (a 34-base-pair tandem repeat in the promoter sequence and a leucine-to-histidine mutation at amino acid 98) and TR 46 /Y121F/T289A (a 46-base-pair tandem repeat in the promoter sequence and mutations at amino acids 121 and 289) 112,113 .”
BackgroundAzole-Resistant Aspergillosis: Epidemiology, Molecular Mechanisms, and Treatment
Chowdhary, A., Sharma, C., & Meis, J. F. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix210 · Cited by 262
The Fungal CYP51s: Their Functions, Structures, Related Drug Resistance, and Inhibitors
Zhang, J., Li, L., Lv, Q., Yan, L., Wang, Y., & Jiang, Y. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00691 · Cited by 245
Rhodes, J., Abdolrasouli, A., Dunne, K., Sewell, T. R., Zhang, Y., Ballard, E., Brackin, A. P., van Rhijn, N., Chown, H., Tsitsopoulou, A., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01091-2 · Cited by 244
Aspergillus fumigatus and aspergillosis: From basics to clinics
Arastehfar, A., Carvalho, A., Houbraken, J., Lombardi, L., Garcia-Rubio, R., Jenks, J. D., Rivero-Menendez, O., Aljohani, R., Jacobsen, I. D., Berman, J., et al. (2021) · Studies in Mycology · doi:10.1016/j.simyco.2021.100115 · Cited by 241
Resistance to antifungals that target CYP51
Parker, J. E., Warrilow, A. G. S., Price, C. L., Mullins, J. G. L., Kelly, D. E., & Kelly, S. L. (2014) · Journal of Chemical Biology · doi:10.1007/s12154-014-0121-1 · Cited by 204
“The CYP51A point mutations G54, G138, M220 and G448 are thought to have arisen during triazole therapy of patients in the clinic, whilst TR34/L98H and TR46/Y121F/T289A (which both contain tandem repeats in the promoter region of the gene) are thought to have arisen in the environment in the Netherlands as a response t…”
BackgroundResultInfluentialAzole resistance in Aspergillus fumigatus: a growing public health concern
Vermeulen, E., Lagrou, K., & Verweij, P. E. (2013) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000005 · Cited by 204
Self-citationTriazole resistance in Aspergillus fumigatus: recent insights and challenges for patient management
Lestrade, P. P. A., Meis, J. F., Melchers, W. J. G., & Verweij, P. E. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.11.027 · Cited by 202
Self-citationEmergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany
Steinmann, J., Hamprecht, A., Vehreschild, M. J. G. T., Cornely, O. A., Buchheidt, D., Spiess, B., Koldehoff, M., Buer, J., Meis, J. F., & Rath, P.-M. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku566 · Cited by 185
Thompson, G. R., & Young, J.-A. H. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2027424 · Cited by 184
Epidemiology and molecular mechanisms of antifungal resistance in Candida and Aspergillus
Gonçalves, S. S., Souza, A. C. R., Chowdhary, A., Meis, J. F., & Colombo, A. L. (2016) · Mycoses · doi:10.1111/myc.12469 · Cited by 180
Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021
Douglas, A. P., Smibert, O. C., Bajel, A., Halliday, C. L., Lavee, O., McMullan, B., Yong, M. K., van Hal, S. J., Chen, S. C. ‐., & the Australasian Antifungal Guidelines Steering Committee (2021) · Internal Medicine Journal · doi:10.1111/imj.15591 · Cited by 179
Abdolrasouli, A., Rhodes, J., Beale, M. A., Hagen, F., Rogers, T. R., Chowdhary, A., Meis, J. F., Armstrong-James, D., & Fisher, M. C. (2015) · mBio · doi:10.1128/mbio.00536-15 · Cited by 177
Zumla, A., Al-Tawfiq, J. A., Enne, V. I., Kidd, M., Drosten, C., Breuer, J., Muller, M. A., Hui, D., Maeurer, M., Bates, M., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70827-8 · Cited by 175
“21 Other newly emergent respiratory pathogen threats that merit close monitoring for expanding epidemic potential include avian infl uenza A H7N9, 22 infl uenza A swine H3N2v and H1N1v variant, 23 human adenovirus 14p1, 24 and rhinovirus group C, 25 each of which have caused localised outbreaks of great concern.”
BackgroundUpdate on Antifungal Drug Resistance
Perlin, D. S., Shor, E., & Zhao, Y. (2015) · Current Clinical Microbiology Reports · doi:10.1007/s40588-015-0015-1 · Cited by 174
Azole resistance mechanisms in Aspergillus: update and recent advances
Pérez-Cantero, A., López-Fernández, L., Guarro, J., & Capilla, J. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.09.011 · Cited by 172
A New Age in Molecular Diagnostics for Invasive Fungal Disease: Are We Ready?
Kidd, S. E., Chen, S. C.-A., Meyer, W., & Halliday, C. L. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02903 · Cited by 166
“…described (Chowdhary et al., 2014) and in azole-resistant environmental isolates, mutations in the tandem base pair repeats of the promoter region of CYP51A coupled to amino acid substitutions in cyp51A leading to the following changes – TR34/L98H and TR46/Y121F/T289A (van der Linden et al., 2013).”
BackgroundEnvironmental Hotspots for Azole Resistance Selection of Aspergillus fumigatus , the Netherlands
Schoustra, S. E., Debets, A. J. M., Rijs, A. J. M. M., Zhang, J., Snelders, E., Leendertse, P. C., Melchers, W. J. G., Rietveld, A. G., Zwaan, B. J., & Verweij, P. E. (2019) · Emerging Infectious Diseases · doi:10.3201/eid2507.181625 · Cited by 164
Self-citationTriazole Resistance in Aspergillus Species: An Emerging Problem
Garcia‐Rubio, R., Cuenca‐Estrella, M., & Mellado, E. (2017) · Drugs · doi:10.1007/s40265-017-0714-4 · Cited by 173
“First detected in 2009 in a Dutch patient [78] it has recently been reported in clinical and environmental isolates from Belgium, France, Denmark, Germany, Spain, China, India, Japan, USA, Colombia,”
BackgroundToda, M., Beer, K. D., Kuivila, K. M., Chiller, T. M., & Jackson, B. R. (2021) · Environmental Health Perspectives · doi:10.1289/ehp7484 · Cited by 161
“…identi fi ed a second genotype, TR 46 /Y121F/T289A ( TR 46 ), thought to be linked to fungicide use (Astvad et al. 2014; Chowdhary et al. 2014b, 2015; Lavergne et al. 2015; Le Pape et al. 2016; Montesinos et al. 2014; Steinmann et al. 2015; van der Linden et al. 2013, 2015; Vermeulen et al. 2012).”
Hargrove, T. Y., Wawrzak, Z., Lamb, D. C., Guengerich, F. P., & Lepesheva, G. I. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.677310 · Cited by 160
“fumigatus resistance to clinically used azoles can be acquired through long time use in the environment (24).”
BackgroundBurks, C., Darby, A., Gómez Londoño, L., Momany, M., & Brewer, M. T. (2021) · PLOS Pathogens · doi:10.1371/journal.ppat.1009711 · Cited by 159
Fungal Lanosterol 14α-demethylase: A target for next-generation antifungal design
Monk, B. C., Sagatova, A. A., Hosseini, P., Ruma, Y. N., Wilson, R. K., & Keniya, M. V. (2019) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2019.02.008 · Cited by 164
Chong, G.-L. M., van de Sande, W. W. J., Dingemans, G. J. H., Gaajetaan, G. R., Vonk, A. G., Hayette, M.-P., van Tegelen, D. W. E., Simons, G. F. M., & Rijnders, B. J. A. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.03216-14 · Cited by 152
“One sample had the TR46-Y121F-T289A mutations, and the other had the TR34-L98H mutations.”
BackgroundInfluentialSelf-citationTriazole resistance surveillance in Aspergillus fumigatus
Resendiz Sharpe, A., Lagrou, K., Meis, J. F., Chowdhary, A., Lockhart, S. R., Verweij, P. E., & on behalf of the ISHAM/ECMM Aspergillus Resistance Surveillance working group (2018) · Medical Mycology · doi:10.1093/mmy/myx144 · Cited by 150
Self-citationGsaller, F., Hortschansky, P., Furukawa, T., Carr, P. D., Rash, B., Capilla, J., Müller, C., Bracher, F., Bowyer, P., Haas, H., et al. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1005775 · Cited by 133
“These SREs are also evident in the overlapping TR46 and TR53 found in other resistant clinical isolates (Fig 5A) [28,29,30].”
BackgroundTriazole Resistance in Aspergillus spp.: A Worldwide Problem?
Rivero-Menendez, O., Alastruey-Izquierdo, A., Mellado, E., & Cuenca-Estrella, M. (2016) · Journal of Fungi · doi:10.3390/jof2030021 · Cited by 142
Alvarez-Moreno, C., Lavergne, R.-A., Hagen, F., Morio, F., Meis, J. F., & Le Pape, P. (2017) · Scientific Reports · doi:10.1038/srep45631 · Cited by 141
Verweij, P. E., Zhang, J., Debets, A. J. M., Meis, J. F., van de Veerdonk, F. L., Schoustra, S. E., Zwaan, B. J., & Melchers, W. J. G. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30138-4 · Cited by 140
Self-citationChowdhary, A., Sharma, C., Hagen, F., & Meis, J. F. (2014) · Future Microbiology · doi:10.2217/fmb.14.27 · Cited by 130
Multi-azole-resistant Aspergillus fumigatus in the environment in Tanzania
Chowdhary, A., Sharma, C., van den Boom, M., Yntema, J. B., Hagen, F., Verweij, P. E., & Meis, J. F. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku259 · Cited by 135
Self-citationChong, G. M., van der Beek, M. T., von dem Borne, P. A., Boelens, J., Steel, E., Kampinga, G. A., Span, L. F. R., Lagrou, K., Maertens, J. A., Dingemans, G. J. H., et al. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw323 · Cited by 131
Self-citationAzole-resistant Aspergillus fumigatus with the environmental TR46/Y121F/T289A mutation in India
Chowdhary, A., Sharma, C., Kathuria, S., Hagen, F., & Meis, J. F. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt397 · Cited by 127
Arendrup, M. C., Cuenca-Estrella, M., Lass-Flörl, C., & Hope, W. W. (2013) · Drug Resistance Updates · doi:10.1016/j.drup.2014.01.001 · Cited by 129
Zhang, J., Snelders, E., Zwaan, B. J., Schoustra, S. E., Meis, J. F., van Dijk, K., Hagen, F., van der Beek, M. T., Kampinga, G. A., Zoll, J., et al. (2017) · mBio · doi:10.1128/mbio.00791-17 · Cited by 129
Self-citationCurrent status of antifungal resistance and its impact on clinical practice
Alcazar‐Fuoli, L., & Mellado, E. (2014) · British Journal of Haematology · doi:10.1111/bjh.12896 · Cited by 117
Sagatova, A. A., Keniya, M. V., Wilson, R. K., Sabherwal, M., Tyndall, J. D. A., & Monk, B. C. (2016) · Scientific Reports · doi:10.1038/srep26213 · Cited by 117
Snelders, E., Camps, S. M. T., Karawajczyk, A., Rijs, A. J. M. M., Zoll, J., Verweij, P. E., & Melchers, W. J. G. (2015) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2015.06.001 · Cited by 127
Self-citationFungicide effects on human fungal pathogens: Cross-resistance to medical drugs and beyond
Bastos, R. W., Rossato, L. L., Goldman, G. H., & Santos, D. A. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1010073 · Cited by 129
“%) in the Netherlands, United Kingdom, and Germany [43,44].”
BackgroundInfluentialChowdhary, A., Sharma, C., Kathuria, S., Hagen, F., & Meis, J. F. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.00428 · Cited by 111
“…et al., 2008; Snelders et al., 2008, 2009; Baddley et al., 2009; Howard et al., 2009; Arendrup et al., 2010; Mortensen et al., 2010, 2011; van der Linden et al., 2011, 2013; Burgel et al., 2012; Chowdhary et al., 2012a,b, 2013b, 2014a,b; AlastrueyIzquierdo et al., 2013; Badali et al.,…”
Antifungals: From Pharmacokinetics to Clinical Practice
do Carmo, A., Rocha, M. J., Pereirinha, P., Tomé, R., & Costa, E. (2023) · Antibiotics · doi:10.3390/antibiotics12050884 · Cited by 132
“However, in recent years, Aspergillus fumigatus , one of the main entities associated with invasive aspergillosis, developed mech-Antibiotics anisms that showed high resistance to voriconazole and were associated with treatment failure [34,77–80].”
BackgroundGauthier, G. M., & Keller, N. P. (2013) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2013.08.016 · Cited by 128
Dudakova, A., Spiess, B., Tangwattanachuleeporn, M., Sasse, C., Buchheidt, D., Weig, M., Groß, U., & Bader, O. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00095-16 · Cited by 113
“For all other mutations, including so far unknown ones, PCR amplification of the gene in either a single (3, 18, 45, 50, 68, 82, 104, 168) or multiple (16, 44, 54, 56, 60, 62, 63, 75, 84, 100, 157, 169–171) amplicons plus subsequent sequencing is necessary.”
BackgroundAzole Resistance in Dermatophytes
Ghannoum, M. A. (2015) · Journal of the American Podiatric Medical Association · doi:10.7547/14-109 · Cited by 125
Drug Strategies Targeting CYP51 in Neglected Tropical Diseases
Choi, J. Y., Podust, L. M., & Roush, W. R. (2014) · Chemical Reviews · doi:10.1021/cr5003134 · Cited by 117
Ren, J., Jin, X., Zhang, Q., Zheng, Y., Lin, D., & Yu, Y. (2016) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2016.12.013 · Cited by 115
Zumla, A. I., Memish, Z. A., Maeurer, M. J., Bates, M., Mwaba, P., Al‐Tawfiq, J. A., Denning, D. W., Hayden, F. G., & Hui, D. S. C. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70828-x · Cited by 116
van Ingen, J., van der Lee, H. A., Rijs, T. A. J., Zoll, J., Leenstra, T., Melchers, W. J. G., & Verweij, P. E. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku364 · Cited by 101
Self-citationEnvironmental Isolates of Azole-Resistant Aspergillus fumigatus in Germany
Bader, O., Tünnermann, J., Dudakova, A., Tangwattanachuleeporn, M., Weig, M., & Groß, U. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00100-15 · Cited by 99
“Isolates with TR46/Y121F/T289A have uniformly been linked to therapeutic failure for treatment of invasive aspergillosis (5, 18).”
van Paassen, J., Russcher, A., in 't Veld - van Wingerden, A. W., Verweij, P. E., & Kuijper, E. J. (2016) · Eurosurveillance · doi:10.2807/1560-7917.es.2016.21.30.30300 · Cited by 97
“Introduction Azole resistance is an emerging problem in Aspergillus infections caused by Aspergillus fumigatus, with increasing reports of azole treatment failure [1-6].”
BackgroundResultSelf-citationBuil, J. B., Rijs, A. J. M. M., Meis, J. F., Birch, M., Law, D., Melchers, W. J. G., & Verweij, P. E. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx177 · Cited by 101
Self-citationAntifungal drug resistance mechanisms in pathogenic fungi: from bench to bedside
Cuenca‐Estrella, M. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12495 · Cited by 109
“Resistance due to the tandem repeat has been linked to the use of azole fungicides in agriculture and gardening [27,28,39].”
BackgroundThe role of azoles in the management of azole-resistant aspergillosis: From the bench to the bedside
Seyedmousavi, S., Mouton, J. W., Melchers, W. J. G., Brüggemann, R. J. M., & Verweij, P. E. (2014) · Drug Resistance Updates · doi:10.1016/j.drup.2014.06.001 · Cited by 107
Self-citationAstvad, K. M. T., Jensen, R. H., Hassan, T. M., Mathiasen, E. G., Thomsen, G. M., Pedersen, U. G., Christensen, M., Hilberg, O., & Arendrup, M. C. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02855-14 · Cited by 95
“lates from domestic homes throughout the Netherlands (20).”
BackgroundInfluentialFacilitators of adaptation and antifungal resistance mechanisms in clinically relevant fungi
Hokken, M., Zwaan, B. J., Melchers, W. J. G., & Verweij, P. E. (2019) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2019.103254 · Cited by 110
Self-citationResendiz-Sharpe, A., Mercier, T., Lestrade, P. P. A., van der Beek, M. T., von dem Borne, P. A., Cornelissen, J. J., De Kort, E., Rijnders, B. J. A., Schauwvlieghe, A. F. A. D., Verweij, P. E., et al. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz258 · Cited by 86
Self-citationNationwide Surveillance of Azole Resistance in Aspergillus Diseases
Vermeulen, E., Maertens, J., De Bel, A., Nulens, E., Boelens, J., Surmont, I., Mertens, A., Boel, A., & Lagrou, K. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00233-15 · Cited by 92
“In the latter, only a few predominant resistance mechanisms occur, namely, the CYP51A alterations TR34/ L98H and TR46/Y121F/T289A (4, 5).”
InfluentialAspergillus fumigatus and pan-azole resistance: who should be concerned?
Wiederhold, N. P., & Verweij, P. E. (2020) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000662 · Cited by 94
Self-citationEnvironmental fungicides and triazole resistance in Aspergillus
Bowyer, P., & Denning, D. W. (2014) · Pest Management Science · doi:10.1002/ps.3567 · Cited by 87
“40 Some triazole fungicides have a similar 3D structure to the three medical triazoles (Fig.”
BackgroundAtrR Is an Essential Determinant of Azole Resistance in Aspergillus fumigatus
Paul, S., Stamnes, M., Thomas, G. H., Liu, H., Hagiwara, D., Gomi, K., Filler, S. G., & Moye-Rowley, W. S. (2019) · mBio · doi:10.1128/mbio.02563-18 · Cited by 91
Passive Surveillance for Azole-Resistant Aspergillus fumigatus, United States, 2011–2013
Pham, C. D., Reiss, E., Hagen, F., Meis, J. F., & Lockhart, S. R. (2014) · Emerging Infectious Diseases · doi:10.3201/eid2009.140142 · Cited by 88
Chen, Y., Lu, Z., Zhao, J., Zou, Z., Gong, Y., Qu, F., Bao, Z., Qiu, G., Song, M., Zhang, Q., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01005-16 · Cited by 85
Self-citationRogers, T. R., Verweij, P. E., Castanheira, M., Dannaoui, E., White, P. L., Arendrup, M. C., Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST), Arendrup, M. C., Arikan-Akdagli, S., Barchiesi, F., et al. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac161 · Cited by 82
Self-citationGisi, U. (2014) · Pest Management Science · doi:10.1002/ps.3664 · Cited by 78
Nucci, M., & Anaissie, E. J. (2014) · Blood · doi:10.1182/blood-2014-04-516211 · Cited by 81
Angeles, L. F., Islam, S., Aldstadt, J., Saqeeb, K. N., Alam, M., Khan, M. A., Johura, F.-T., Ahmed, S. I., & Aga, D. S. (2020) · Science of The Total Environment · doi:10.1016/j.scitotenv.2019.136285 · Cited by 80
Fischer, J., van Koningsbruggen-Rietschel, S., Rietschel, E., Vehreschild, M. J. G. T., Wisplinghoff, H., Kronke, M., & Hamprecht, A. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku009 · Cited by 75
Mechanisms of triazole resistance in Aspergillus fumigatus
Nywening, A. V., Rybak, J. M., Rogers, P. D., & Fortwendel, J. R. (2020) · Environmental Microbiology · doi:10.1111/1462-2920.15274 · Cited by 87
“Mutations affecting the target enzymes of triazoles, the fungal sterol 14α-demethylases, represent the most commonly identified mechanisms associated with triazole resistance in A. fumigatus (Snelders et al., 2010; Denning et al., 2011; van der Linden et al., 2013).”
BackgroundInfluentialMelo, A. M., Stevens, D. A., Tell, L. A., Veríssimo, C., Sabino, R., & Xavier, M. O. (2020) · Microorganisms · doi:10.3390/microorganisms8122037 · Cited by 86
Kasahara, S., Jhingran, A., Dhingra, S., Salem, A., Cramer, R. A., & Hohl, T. M. (2016) · Journal of Infectious Diseases · doi:10.1093/infdis/jiw054 · Cited by 71
“Given the rising incidence of antifungal drug resistance among clinical and environmental Aspergillus isolates [50], further studies to optimize adjunctive treatment strategies”
BackgroundAhmad, S., Khan, Z., Hagen, F., & Meis, J. F. G. M. (2014) · Environmental Research · doi:10.1016/j.envres.2014.05.009 · Cited by 78
Lavergne, R.-A., Morio, F., Favennec, L., Dominique, S., Meis, J. F., Gargala, G., Verweij, P. E., & Le Pape, P. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00127-15 · Cited by 69
“Aspergillus fumigatus isolates carrying the TR46/Y121F/T289A mutation were first described in December 2009 in The Netherlands (2).”
BackgroundInfluentialSelf-citationAntifungal resistance in dermatology
Pai, V. V., Ganavalli, A., & Kikkeri, N. (2018) · Indian Journal of Dermatology · doi:10.4103/ijd.ijd_131_17 · Cited by 89
“A strong link has been found between countries where azole-based fungicides are used and the incidence of antifungal resistance.[21,24]”
Nabili, M., Shokohi, T., Moazeni, M., Khodavaisy, S., Aliyali, M., Badiee, P., Zarrinfar, H., Hagen, F., & Badali, H. (2016) · Journal of Medical Microbiology · doi:10.1099/jmm.0.000255 · Cited by 76
“Recently, van der Linden et al. (2013) described a novel CYP51A-mediated resistance mechanism, consisting of two amino acid substitutions and a 46 bp tandem repeat in the TR46/Y121F/T289A gene promoter region.”
BackgroundAzole-resistant Aspergillus fumigatus in sawmills of Eastern France
Jeanvoine, A., Rocchi, S., Reboux, G., Crini, N., Crini, G., & Millon, L. (2017) · Journal of Applied Microbiology · doi:10.1111/jam.13488 · Cited by 66
“…Hampshire, UK), and two malt agars supplemented, respectively, with 2 mg l 1 of itraconazole (Maltitra) and 1 mg l 1 of voriconazole (Maltvori) (van der Linden et al. 2013; Bader et al. 2015), using MAS-100 NT™ impactor (Merck , Darmstadt, Germany) with a flow rate of 100 l of air per minute.”
InfluentialAzole-resistant Aspergillus fumigatus: A global phenomenon originating in the environment?
Jeanvoine, A., Rocchi, S., Bellanger, A., Reboux, G., & Millon, L. (2019) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2019.07.014 · Cited by 73
Tyndall, J. D. A., Sabherwal, M., Sagatova, A. A., Keniya, M. V., Negroni, J., Wilson, R. K., Woods, M. A., Tietjen, K., & Monk, B. C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167485 · Cited by 77
Bartlett, A. W., Cann, M. P., Yeoh, D. K., Bernard, A., Ryan, A. L., Blyth, C. C., Kotecha, R. S., McMullan, B. J., Moore, A. S., Haeusler, G. M., et al. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27564 · Cited by 70
Perfect, J. R., Hachem, R. Y., & Wingard, J. R. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu639 · Cited by 74
“Aspergillus isolates [28] and its presence should be monitored.”
BackgroundInvestigating Clinical Issues by Genotyping of Medically Important Fungi: Why and How?
Alanio, A., Desnos‐Ollivier, M., Garcia‐Hermoso, D., & Bretagne, S. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00043-16 · Cited by 71
“The inhalation of azole-resistant isolates is the second mechanism for developing azole-resistant IA. Azole-resistant isolates with a promoter duplication (TR34) and point mutation (L98H) in the CYP51A, which have been well described in The Netherlands, clustered together using MLP typing in a clade separated from azo…”
Hachem, R. Y., Gomes, M. Z. R., Helou, G., Zakhem, A. E., Kassis, C., Ramos, E., Jiang, Y., Chaftari, A., & RAAD, I. I. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku241 · Cited by 72
Isolation of azole-resistant Aspergillus fumigatus from the environment in the south-eastern USA
Hurst, S. F., Berkow, E. L., Stevenson, K. L., Litvintseva, A. P., & Lockhart, S. R. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx168 · Cited by 66
Lavergne, R.-A., Chouaki, T., Hagen, F., Toublanc, B., Dupont, H., Jounieaux, V., Meis, J. F., Morio, F., & Le Pape, P. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw664 · Cited by 60
“environmental TR46/Y121F/T289A azole-resistant isolates were genetically related [3].”
BackgroundPaul, S. K., Diekema, D. J., & Moye-Rowley, S. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02748-16 · Cited by 70
Sewell, T. R., Zhang, Y., Brackin, A. P., Shelton, J. M. G., Rhodes, J., & Fisher, M. C. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00548-19 · Cited by 62
“All the TR34/L98H and TR46/Y121F/T289A isolates predominantly belonged to csp1 subtype t02.”
BackgroundInfluentialPrimary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia
Halpern, A. B., Lyman, G. H., Walsh, T. J., Kontoyiannis, D. P., & Walter, R. B. (2015) · Blood · doi:10.1182/blood-2015-07-627323 · Cited by 64
Jensen, R. H., Hagen, F., Astvad, K. M. T., Tyron, A., Meis, J. F. G. M., & Arendrup, M. C. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.04.001 · Cited by 61
Arendrup, M. C., Verweij, P. E., Mouton, J. W., Lagrou, K., & Meletiadis, J. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx319 · Cited by 66
Self-citation
Metadata
- Authors
- van der Linden, J. W. M., Camps, S. M. T., Kampinga, G. A., Arends, J. P. A., Debets-Ossenkopp, Y. J., Haas, P. J. A., Rijnders, B. J. A., Kuijper, E. J., van Tiel, F. H., Varga, J., Karawajczyk, A., Zoll, J., Melchers, W. J. G., & Verweij, P. E.
- Affiliations
- Radboud University Nijmegen (NL)
- University Medical Center Groningen (NL)
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- University Medical Center Utrecht (NL)
- Erasmus MC (NL)
- Leiden University Medical Center (NL)
- University of Szeged (HU)
- Radboud University Medical Center (NL)
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-05-10
- Volume
- 57
- Issue
- 4
- Pages
- 513-520
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2142912010
- Cited by
- 342
- References
- 31
- Citations by year
- 2026: 5 · 2025: 17 · 2024: 15 · 2023: 21 · 2022: 13 · 2021: 28 · 2020: 25 · 2019: 21 · 2018: 32 · 2017: 38 · 2016: 38 · 2015: 40 · 2014: 34 · 2013: 13
- FWCI
- 30.27
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- Pfizer
- Gilead Sciences
- ZonMw
- Astellas Pharma
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- Aspergillus fumigatus, voriconazole resistance, azole resistance, invasive aspergillosis, cyp51A mutations, azole fungicides, environmental isolates, treatment failure, antifungal resistance surveillance
- MeSH terms
- Aged, Air Microbiology, Antifungal Agents, Aspergillosis, Aspergillus fumigatus, Child, Female, Genes, Fungal, Genotype, Hospitals, Humans, Male, Middle Aged, Netherlands, Pyrimidines, Surveys and Questionnaires, Residence Characteristics, Selection, Genetic, Triazoles, Mycological Typing Techniques, Treatment Failure, Sequence Analysis, DNA, Drug Resistance, Fungal, Young Adult, Molecular Typing, Voriconazole
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.